Get the Stockscreener App
102.67
0.78%
0.79
After Hours:
102.67
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $102.67, with a volume of 12.44M.
It is up +0.78% in the last 24 hours and down -11.76% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$101.88
Open:
$102.54
24h Volume:
12.44M
Relative Volume:
1.15
Market Cap:
$178.41B
Revenue:
$44.33B
Net Income/Loss:
$6.50B
P/E Ratio:
27.62
EPS:
3.717
Net Cash Flow:
$7.40B
1W Performance:
-1.34%
1M Performance:
-11.76%
6M Performance:
-23.35%
1Y Performance:
-22.60%
1-Day Range:
$100.88
$103.68
1-Week Range:
$100.88
$105.98
52-Week Range:
$100.88
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
102.67 | 177.03B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
328.59 | 124.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.65 | 110.08B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.75 | 93.53B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.08 | 45.84B | 6.07B | 1.06B | 1.34B | 1.8063 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Oncology Integration Into OncoEMR Tests Long Term Growth Story - simplywall.st
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Abbott Laboratories (ABT) - The Globe and Mail
BTIG Research Lowers Abbott Laboratories (NYSE:ABT) Price Target to $131.00 - MarketBeat
BTIG Research Adjusts Abbott Laboratories PT to $131 From $140, Maintains Buy Rating - marketscreener.com
Whoop Raises $575M at $10.1B Valuation, Abbott Joins as Investor - Athletech News
Abbott Laboratories $ABT Position Trimmed by J. Safra Sarasin Holding AG - MarketBeat
Abbott Laboratories $ABT Shares Bought by Mn Services Vermogensbeheer B.V. - MarketBeat
Abbott (ABT) Enhances Cancer Care with OncoEMR Test Integration - GuruFocus
Abbott (ABT) Dips More Than Broader Market: What You Should Know - Yahoo Finance Australia
Dairy industry consolidation | Lactalis, Abbott Complete Major NZ Dairy Deals - en.edairynews.com
SCHD ETF Rebalance Adds Abbott, UnitedHealth as Dividend Fund Inflows Hit 4-Year High - TechStock²
Abbott, Flatiron Health Integrate Precision Oncology Tests Into Oncology EMR Platform - Clinical Lab Products
Abbott Laboratories stock hits 52-week low at 102.39 USD - Investing.com
Abbott Laboratories stock hits 52-week low at 102.39 USD By Investing.com - Investing.com Australia
Abbott integrates Precision Oncology portfolio into Flatiron’s OncoEMR - TipRanks
Abbott integrates cancer tests into Flatiron’s EMR platform By Investing.com - Investing.com India
Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform - marketscreener.com
4,700 cancer providers can now order Abbott tests in their records system - Stock Titan
This Top ETF Recently Added a Healthy Dose of These High-Yielding Dividend Stocks - The Motley Fool
Inside the high-stakes business battle over feeding preterm babies - usatoday.com
Is Abbott Laboratories (ABT) Offering Value After Recent Share Price Weakness? - simplywall.st
Chesley Taft & Associates LLC Has $30.29 Million Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Net Worth Advisory Group Acquires Shares of 10,905 Abbott Laboratories $ABT - MarketBeat
Abbott subsidiary dodges whistleblower claim from fired remote worker - hcamag.com
Abbott Culture Alignment Supports Long Term Execution And Valuation Story - simplywall.st
Abbott Laboratories (ABT) announces completion of acquisition of Exact Sciences - MSN
Abbott Laboratories Faces Weak Start with Gap Down Amid Market Concerns - marketsmojo.com
Abbott Labs Eludes Kentucky State-Law Claims in Heart Valve Suit - Bloomberg Law News
Clinical Nutrition for Diabetes Care Market Report 2026-2030 Featuring Profiles of Key PlayersPfizer, Bayer, Sanofi-Aventis, Abbott Labs, Roche and More - GlobeNewswire
Abbott Laboratories Revenue Breakdown – BSESOF:ABL - TradingView
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), Merck & Company (MRK) and Abbott Laboratories (ABT) - The Globe and Mail
Abbott Laboratories $ABT Shares Acquired by Dakota Wealth Management - MarketBeat
Abbott Unit Beats Ex-Worker's Whistleblower Suit At 8th Circ. - Law360
Vanguard disaggregates holdings; ABT shows 0 shares (ABT) - Stock Titan
Abbott Labs Worker’s Wrongful Termination Suit Fails on Appeal - Bloomberg Law News
What Abbott Laboratories (ABT)'s Cancer Screening Deal and Libre Data Reveal About Its Chronic Care Ambitions - simplywall.st
Abbott Laboratories (ABT) Announces Completion of Acquisition of Exact Sciences - Yahoo Finance
NEC Baby Formula Lawsuit & Settlement | March 2026 Update - lawsuit-information-center.com
Abbott Laboratories (ABT) Stock Price, Trades & News - GuruFocus
Abbott hosts conference call for first-quarter earnings - Abbott MediaRoom
Abbott will report first-quarter results before markets open April 16 - Stock Titan
Abbott Laboratories stock faces pipeline scrutiny amid diagnostics slowdown in Q1 2026 - AD HOC NEWS
Abbott (NYSE: ABT) SVP receives 13,255-share restricted stock award - Stock Titan
[Form 3] ABBOTT LABORATORIES Initial Statement of Beneficial Ownership - Stock Titan
Mom Tying Abbott Formula To Baby's NEC Takes The Stand - Law360
Why Abbott (ABT) Is Betting $23B on Cancer Screening - MarketWise
Abbott Earnings Preview: What to Expect - Barchart.com
Pensionfund Sabic Takes Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock Hits Day Low of $105.40 Amid Price Pressure - Markets Mojo
Abbott Laboratories Hits New 52-Week Low at USD 104.11 - Markets Mojo
Abbott Laboratories stock faces pressure amid diagnostics slowdown and FreeStyle Libre competition i - AD HOC NEWS
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.76%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):